[PPB] QoQ Cumulative Quarter Result on 31-Dec-2023 [#4]

Stock
[PPB] PPB GROUP BHD
Announcement Date
28-Feb-2024
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2023
Quarter
31-Dec-2023 [#4]
Profit Trend
QoQ- 46.32%
YoY- -36.53%
Quarter Report
Latest QR
Upcoming QR
PPB's Result
PPB's Financial Summary
View:
Show?
Cumulative Result
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
Revenue 3,955,284 2,606,557 1,287,555 5,720,693 4,458,203 3,000,609 1,519,675 88.88%
PBT 910,207 701,115 367,597 1,488,474 1,046,757 647,838 415,014 68.56%
Tax -58,548 -40,822 -18,270 -67,835 -62,473 -47,449 -22,496 88.87%
NP 851,659 660,293 349,327 1,420,639 984,284 600,389 392,518 67.36%
-
NP to SH 854,210 646,090 337,171 1,394,305 952,905 580,351 377,537 72.09%
-
Tax Rate 6.43% 5.82% 4.97% 4.56% 5.97% 7.32% 5.42% -
Total Cost 3,103,625 1,946,264 938,228 4,300,054 3,473,919 2,400,220 1,127,157 96.08%
-
Net Worth 25,206,662 27,555,760 27,754,923 27,128,978 26,958,268 26,844,460 26,488,810 -3.24%
Dividend
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
Div 170,699 170,711 - 597,491 170,711 170,711 - -
Div Payout % 19.98% 26.42% - 42.85% 17.91% 29.42% - -
Equity
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
Net Worth 25,206,662 27,555,760 27,754,923 27,128,978 26,958,268 26,844,460 26,488,810 -3.24%
NOSH 1,422,497 1,422,599 1,422,599 1,422,599 1,422,599 1,422,599 1,422,599 -0.00%
Ratio Analysis
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
NP Margin 21.53% 25.33% 27.13% 24.83% 22.08% 20.01% 25.83% -
ROE 3.39% 2.34% 1.21% 5.14% 3.53% 2.16% 1.43% -
Per Share
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
RPS 278.05 183.22 90.51 402.13 313.38 210.92 106.82 88.89%
EPS 60.05 45.42 23.70 98.01 66.98 40.80 26.54 72.09%
DPS 12.00 12.00 0.00 42.00 12.00 12.00 0.00 -
NAPS 17.72 19.37 19.51 19.07 18.95 18.87 18.62 -3.24%
Adjusted Per Share Value based on latest NOSH - 1,422,599
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
RPS 278.04 183.23 90.51 402.14 313.39 210.93 106.83 88.88%
EPS 60.05 45.42 23.70 98.01 66.99 40.80 26.54 72.09%
DPS 12.00 12.00 0.00 42.00 12.00 12.00 0.00 -
NAPS 17.7193 19.3706 19.5106 19.0706 18.9506 18.8706 18.6206 -3.24%
Price Multiplier on Financial Quarter End Date
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
Date 30/09/24 28/06/24 29/03/24 29/12/23 29/09/23 30/06/23 31/03/23 -
Price 14.46 14.30 15.38 14.48 15.48 15.74 16.56 -
P/RPS 5.20 7.80 16.99 3.60 4.94 7.46 15.50 -51.62%
P/EPS 24.08 31.49 64.89 14.77 23.11 38.58 62.40 -46.90%
EY 4.15 3.18 1.54 6.77 4.33 2.59 1.60 88.45%
DY 0.83 0.84 0.00 2.90 0.78 0.76 0.00 -
P/NAPS 0.82 0.74 0.79 0.76 0.82 0.83 0.89 -5.30%
Price Multiplier on Announcement Date
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
Date 28/11/24 29/08/24 30/05/24 28/02/24 29/11/23 29/08/23 31/05/23 -
Price 13.28 14.34 14.74 15.32 13.98 15.76 16.26 -
P/RPS 4.78 7.83 16.29 3.81 4.46 7.47 15.22 -53.69%
P/EPS 22.11 31.57 62.19 15.63 20.87 38.63 61.27 -49.21%
EY 4.52 3.17 1.61 6.40 4.79 2.59 1.63 97.01%
DY 0.90 0.84 0.00 2.74 0.86 0.76 0.00 -
P/NAPS 0.75 0.74 0.76 0.80 0.74 0.84 0.87 -9.39%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment